Trial Profile
An Open-label Phase I, Dose-escalation Study to Evaluate the Safety, Tolerability, Maximum Tolerated Dose, Biodistribution, Radiation Dosimetry and Pharmacokinetics of BAY1862864 Injection in Subjects With Relapsed or Refractory CD22-positive Non-Hodgkin's Lymphoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 21 Feb 2022
Price :
$35
*
At a glance
- Drugs Epratuzumab-Th-227 (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Adverse reactions; First in man
- Sponsors Bayer
- 03 Dec 2019 Status changed from active, no longer recruiting to completed.
- 31 Oct 2019 Planned End Date changed from 11 Dec 2019 to 9 Jan 2020.
- 03 Apr 2019 Planned End Date changed from 30 Oct 2020 to 11 Dec 2019.